GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway
Metrics: PDF 717 views | HTML 1292 views | ?
Jing Xie1, Quan Li2, Xi Ding1 and Yunyun Gao1
1Department of Stomatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Center of Stomatology, The Second Affiliated Hospital of Soochow University, Suzhou, China
Jing Xie, email: firstname.lastname@example.org
Keywords: HNSCC, PI3K-AKT-mTOR, GSK1059615, programmed necrosis
Received: November 23, 2016 Accepted: January 11, 2017 Published: February 07, 2017
This study tested the anti-head and neck squamous cell carcinoma (HNSCC) cell activity by GSK1059615, a novel PI3K and mTOR dual inhibitor. GSK1059615 inhibited survival and proliferation of established (SCC-9, SQ20B and A253 lines) and primary human HNSCC cells. GSK1059615 blocked PI3K-AKT-mTOR activation in HNSCC cells. Intriguingly, GSK1059615 treatment in HNSCC cells failed to provoke apoptosis, but induced programmed necrosis. The latter was tested by mitochondria depolarization, ANT-1-cyclophilin-D mitochondrial association and lactate dehydrogenase (LDH) release. Reversely, mPTP blockers (sanglifehrin A, cyclosporin A and bongkrekic acid) or cyclophilin-D shRNA dramatically alleviated GSK1059615-induced SCC-9 cell death. Further studies demonstrated that GSK1059615 i.p. injection suppressed SCC-9 tumor growth in nude mice, which was compromised with co-administration with cyclosporin A. Thus, targeting PI3K-AKT-mTOR pathway by GSK1059615 possibly provokes programmed necrosis pathway to kill HNSCC cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.